Advancing drug discovery for schizophrenia
Article first published online: 27 OCT 2011
© 2011 New York Academy of Sciences.
Annals of the New York Academy of Sciences
Volume 1236, Annals Meeting Reports pages 30–43, October 2011
How to Cite
Marder, S. R., Roth, B., Sullivan, P. F., Scolnick, E. M., Nestler, E. J., Geyer, M. A., Welnberger, D. R., Karayiorgou, M., Guidotti, A., Gingrich, J., Akbarian, S., Buchanan, R. W., Lieberman, J. A., Conn, P. J., Haggarty, S. J., Law, A. J., Campbell, B., Krystal, J. H., Moghaddam, B., Saw, A., Caron, M. G., George, S. R., Allen, J. A. and Solis, M. (2011), Advancing drug discovery for schizophrenia. Annals of the New York Academy of Sciences, 1236: 30–43. doi: 10.1111/j.1749-6632.2011.06216.x
- Issue published online: 27 OCT 2011
- Article first published online: 27 OCT 2011
Vol. 1259, Issue 1, 145, Article first published online: 3 JUL 2012
- neuronal function;
- small molecules;
Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, “Advancing Drug Discovery for Schizophrenia” was held March 9–11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.